SHP465 isan investigational oral stimulant medication intended to treat adults with ADHD.Two different doses of the drug treated 275 patients with ADHD more effectively than a placebo, according to a recent study led by Matthew Brams, MD, Clinical Assistant Professor at Baylor College of Medicine in Houston
Dublin-based Shire already sells Vynase and Intunic for treatment of the condition, with its ADHD drug franchise patent-protected until 2029.
“ADHD affects adults in multiple ways and, therefore, physicians need additional treatment options. Based upon this study’s findings, and pending the U.S. FDA’s review, SHP465 may provide a promising treatment option for physicians and patients alike,” said Matthew Brams, MD, lead investigator of the study.
Shire plans to submit a New Drug Application to the FDA by the end of the year and hopes to gain approval for SHP465 in late 2017.
More articles on the drug market:
FDA approves drug for treatment of 6 types of hepatitis C
Pfizer to build $350M biotech center in China
Roche’s new MS drug to hit market sooner than expected
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
